{"commentary":{"count":74,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":37,"podcast":19,"x_thread":18},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05171647\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SUNMO","nct_id":"NCT05171647","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunmo-nct05171647. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SUNMO","arms":[{"description":"Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.","label":"M+P (Arm A)","type":"EXPERIMENTAL"},{"description":"Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.","label":"R-GemOx (Arm B)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-02-28","type":"ESTIMATED"},"conditions":["Non-Hodgkin Lymphoma"],"enrollment":{"count":208,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Mosunetuzumab","type":"DRUG"},{"name":"Polatuzumab vedotin","type":"DRUG"},{"name":"Tocilizumab","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"}],"last_update":"2026-08-05","lead_sponsor":"Hoffmann-La Roche","official_title":"A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-02-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)","timeFrame":"Up to approximately 23.8 months"},{"measure":"Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans","timeFrame":"Up to 32 months"}],"references":[{"citation":"Maruyama D, Goto H, Kumode T, Aizawa K, Fukuhara N, Westin JR, Kim WS, Mori C, Imaizumi T, Kato K. Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. Int J Clin Oncol. 2026 Aug;31(8):1547-1556. doi: 10.1007/s10147-026-03042-x. Epub 2026 Jun 15.","pmid":"42298056","type":"DERIVED"},{"citation":"Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah N, Assouline S, Olszewski AJ, Naik S, Ghosh N, Pham S, Wei MC, Batlevi C, To I, Ead W, Makadia S, Penuel E, Jing J, Budde LE. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. Am J Hematol. 2026 Sep;101(9):2177-2189. doi: 10.1002/ajh.70403. Epub 2026 Jun 12.","pmid":"42283231","type":"DERIVED"},{"citation":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. J Clin Oncol. 2025 Dec 20;43(36):3799-3811. doi: 10.1200/JCO-25-01957. Epub 2025 Oct 2.","pmid":"41037766","type":"DERIVED"}],"start_date":{"date":"2022-04-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","url":"https://clinicaltrials.gov/study/NCT05171647"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunmo-nct05171647"}